A Study of Oral Hymecromone and Hyaluronan Synthesis
Status:
Completed
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to add further understanding to the doses of hymecromone that
effectively and safely lead to the inhibition of hyaluronan synthesis. In this study we will
investigate both circulating hyaluronan in the serum, as well as tissue hyaluronan, using
sputum samples as a non-invasive surrogate.
This is a parallel, open-label, single-center, dose-response study of hymecromone in healthy
adults 18 years of age or older. Up to 18 participants will be enrolled. Participants will be
treated for 4 days with study drug. Safety as well as biomarkers of pharmacokinetic and
pharmacodynamic response will be monitored during therapy.